Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 20, 2018. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details the exercise of nil-cost options and subsequent share sales to meet tax liabilities under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions involving company insiders.
| Transaction Type | Instrument | Aggregate Volume | Price Range (GBP) |
|---|---|---|---|
| Option Exercise | Ordinary Shares | 140,765 | £0.0000 |
| Share Sale (Tax) | Ordinary Shares | 73,832 | £13.1028 - £13.1800 |
Material Changes
As this filing is a regulatory notification of specific insider transactions rather than a periodic financial report, there are no material changes to the company's financial position or operations reported herein. The transactions reflect standard compensation plan activities.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) on February 16 and February 19, 2018, to satisfy tax obligations arising from the exercise of deferred bonus awards.
Investor Verification Checklist
- Verify the total number of shares sold by insiders to meet tax liabilities (73,832 shares) against the total number of options exercised (140,765 shares).
- Confirm the transaction dates (February 16 and 19, 2018) align with the company's compensation vesting schedule.
- Note that the sale prices ranged between £13.10 and £13.18, reflecting the market price at the time of execution.
- Identify the specific executives involved: Ms E Walmsley (CEO), Mr R Connor, Mr S Dingemans (CFO), Mr N Hirons, Mr D Redfern, Ms C Thomas, Mr P Thomson, and Dr P Vallance.